#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haematological malignancy Alternating hemiplegia of childhood Post transplant lymphoproliferative disorder Peripheral T-cell lymphoma unspecified Peritoneal mesothelioma malignant Chronic cutaneous lupus erythematosus Stargardt's disease Bone marrow disorder Palmoplantar pustulosis Vitamin B12 deficiency Synovial sarcoma metastatic Acute myeloid leukaemia refractory Salivary gland cancer Thalassaemia Deafness neurosensory More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency – Diagnostics MELAS syndrome – Life with Disease Haemophilia B without inhibitors – Diagnostics Usher’s syndrome – Diagnostics Vascular malformation – Treatment Hereditary neuropathic amyloidosis – Life with Disease CADASIL – Life with Disease Prolymphocytic leukaemia – Treatment Anaplastic thyroid cancer Mantle cell lymphoma stage II – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Medroxyprogesterone Acetate Bt8009 Noradrenaline Tartrate Venlafaxine Hydrochloride Atropine Sulfate Monohydrate NORETHISTERONE ACETATE Sodium Phenylbutyrate TX000045 Carisbamate Lithium Sulphate, Anhydrous ALLERGEN EXTRACTS Azd9550 Hypromellose Lonvoguran Paltusotine Potassium Oxybate Ertapenem Heterodimeric Interleukin-15 Emiplacel Anb032 More therapies…

    Learn about Your Condition

    Skin candida Diabetic foot infection Colorectal cancer metastatic Interstitial lung disease Restless legs syndrome Genital herpes Glucose tolerance impaired Enteritis HIV infection Pneumococcal infection Malignant lymphoid neoplasm B-cell lymphoma recurrent Renal impairment Plasma cell leukaemia Intracranial calcification More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Tirumotecan
    • Carboplatin
    • Gemcitabine Hydrochloride
    Belgium Czechia Denmark Finland France Germany +7

  • Study on Atorvastatin’s Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    • Triple negative breast cancer
    Investigated Drugs:
    • Atorvastatin
    Italy

  • Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Epirubicin Hydrochloride
    • Capecitabine
    Spain

  • Study of [68Ga]Ga-PentixaFor PET-CT Imaging in Patients with Metastatic Triple-Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Pentixafor
    • Gallium (68Ga)
    France

  • Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Pembrolizumab
    Belgium France

  • Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel for Patients with Metastatic Triple-Negative PD-L1 Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Paclitaxel Albumin-Bound
    Italy
Previous Page
1 2 3 4 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!